FDA Approved: DABIGATRAN ETEXILATE — Original Application (Alembic Pharmaceuticals Inc.)

View source ↗

Summary

FDA approves Alembic Pharmaceuticals' Original Application for dabigatan etexilate as a generic version of Pradaxa, an oral anticoagulant indicated for nonvalvu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Deep Vein Thrombosis
• Nonvalvular Atrial Fibrillation
• Pulmonary Embolism

Drugs mentioned

• Dabigatran etexilate (Dabigatran etexilate)

Snippet

ORIG AP for DABIGATRAN ETEXILATE (DABIGATRAN ETEXILATE)